Wegovy

Novo Nordisk asked US regulators to approve the drug for children ages 6 to 11. In the EU, it’s available for adolescents as young as 12. ADVERTISEMENT An obesity drug …

El prximo 1 de mayo llega a Espaa uno de los frmacos ms esperados para luchar contra la obesidad. Se trata de un nuevo anti-GLP-1, semaglutida, desarrollado por Novo Nordisk. …

Americans love to dream of miracle drugs, but hardly anything ever seems to fill the bill. True, semaglutide has arrived with real questions trailing like bunting: Much of the weight …